FDA Accepts Complete Response Submission Regarding the Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
14 août 2012 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") filed on July 31, 2012 with the U.S. Food and Drug Administration its complete...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended June 30, 2012
08 août 2012 15h00 HE
|
Hemispherx Biopharma, Inc.
Resources Directed at Ampligen® New Drug Application and Enhancements to Manufacturing Facility Continue
Net Comprehensive Loss Reduced
PHILADELPHIA, Aug. 8, 2012 (GLOBE NEWSWIRE) --...
Hemispherx Biopharma Files Complete Response With the FDA Regarding Its Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
01 août 2012 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") filed yesterday with the U.S. Food and Drug Administration its complete response to...
Hemispherx Biopharma Announces Filing a New Drug Application in Argentina for Ampligen(R) to Treat Chronic Fatigue Syndrome
18 juil. 2012 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 18, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it has submitted a new drug application to ANMAT (Administracion...
Hemispherx Biopharma and the FDA Reach Agreement on Filing Requirements for the Company's Complete Response in Support of Ampligen(R) New Drug Application for Chronic Fatigue Syndrome Treatment
11 juil. 2012 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 11, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") recently met with representatives of the U.S. Food and Drug Administration (the...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2012
07 mai 2012 16h35 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 7, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced its financial results for the three months ended March 31, 2012. The net loss for the period (including...
Hemispherx Biopharma Announces Test of Ampligen(R) With FluMist
30 avr. 2012 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, April 30, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx"), announced that Ampligen®, an experimental immunotherapeutic, has been...
Hemispherx Publishes Peer-Reviewed Data on an Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies (NABs) Against Recombinant Interferons Versus Natural Human Interferons (IFNs)
26 mars 2012 08h30 HE
|
Hemispherx Biopharma, Inc.
Incidence of NABs Induced Against Natural IFNs, Such as Alferon N Injection®, Was Very Low (<0.2%) and Significantly Less Than for Recombinant IFNs
PHILADELPHIA, March 26, 2012 (GLOBE...
Hemispherx Biopharma, Inc. to Host 2011 Year End Conference Call on Thursday, March 22, 2012
20 mars 2012 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 20, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), has scheduled a conference call and audio webcast on Thursday, March 22, 2012 at 10:00 a.m....
Hemispherx Publishes Data on the Bioactivity of Ampligen(R) in Chronic Fatigue Syndrome ("CFS")
19 mars 2012 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 19, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced the publication of a peer-reviewed article providing the results...